Sheryl Stevenson

The next-generation FSYX ocular pressure adjusting pump adds wireless connectivity to transmit patient usage data to prescribing practices.

Phase 2 and phase 3 results in diabetic macular edema and uveitic macular edema support intravitreal anti–IL-6 therapy

Several presentations at ARVO 2026 show the field advancing on two fronts: extending how long therapies last and broadening what they target.

Three-year durability data emerge for two distinct approaches to RP

Christopher E. Starr, MD, FACS, highlights diagnostic gaps in dry eye, emphasizing neuropathic corneal pain and reviewing emerging therapies and pipeline treatments in ocular surface disease.

A tissue-sparing technique using a triple-layer decellularized basement membrane is associated with shorter OR time, rapid recovery, and no reported recurrences in a retrospective series.

Quesada discusses a robotic femtosecond laser platform for LASIK, focusing on flap accuracy, stromal bed precision, and the role of integrated OCT imaging.

An analysis of lifitegrast trial subgroups showed that earlier treatment and milder baseline disease were associated with faster and greater symptom improvement.

Combining peristaltic and Venturi pump technology during phacoemulsification may reduce ultrasound time and support endothelial preservation.

Dan B. Tran, MD, compared refractive accuracy, cylinder correction, and postoperative adjustment rates between femtosecond laser–assisted and manual capsulotomy in Light Adjustable Lens cases.

George O. Waring IV, MD, FACS, discussed how “tolerance” may expand the QRS functional vision model, with new data on IOL performance in residual astigmatism and defocus.

Oluwatosin U. Smith, MD, provides an overview of angle-based techniques, cyclodialysis cleft repair, and minimally invasive approaches to glaucoma surgical complications.

Expanded guidance incorporates advanced diagnostics and reinforces treatment of conditions such as Demodex blepharitis and neuropathic pain, explains Christopher E. Starr, MD, FACS.

Chang described how the ASCRS Functional Vision Working Group is proposing a structured framework centered on visual quality, visual range, and visual symptoms to guide lens classification.

Bovelle reflects on the significance of this leadership milestone and shares her vision for mentorship, innovation, and global engagement across ophthalmology, optometry, and industry.

The University of Rochester’s Flaum Eye Institute is embedding behavioral health into ophthalmology to improve patient care and clinician support.

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.

Daniela Ferrara, MD, PhD, FASRS, FARVO, discusses how data from low- and middle-income countries can strengthen US trials, improve equity, and inform innovation as the field looks toward 2026.

Risk stratification, patch graft selection, tube repositioning, and multidisciplinary care all play a role in minimizing erosion and protecting long-term outcomes.

Oluwatosin U. Smith, MD, highlights how the foundation provides education, research, and access-to-care for patients and clinicians globally and locally.

Aaron Y. Lee, MD, MSCI, explains how temporal optical coherence tomography modeling may improve longitudinal disease tracking and clinical decision-making at Angiogenesis 2026.

Andrew Tatham, MD, MBA, FRCOphth, FEBO, outlines the role of micro-invasive glaucoma surgery alongside established glaucoma procedures, focusing on safety, patient selection, and future directions.

AI is reshaping clinical practice in retinal imaging and workflow optimization, according to Priv.-Doz. Dr. med. Jan H. Terheyden, FEBO.

Prof. Dr. med. Wolf A. Lagrèze highlights the clinical role, limitations, and future potential of optical coherence tomography in glaucoma and neuro-ophthalmic disease.

As the 2nd International Glaucoma Symposium approaches in Mainz, Germany, Stephan Schulz highlights how the program bridges everyday clinical needs with the latest advances in AI, imaging, and surgery.

The January 31, 2026, conference in Mainz, Germany, will focus on advances in optic neuropathy diagnosis, artificial intelligence applications, and surgical perspectives

Analysis of 20 years of data highlights differences in reimbursement trends across ophthalmology subspecialties and practice settings, according to Dustin D. French, PhD.

As Glaucoma Awareness Month highlights evolving practice, specialists describe how artificial intelligence, sustained drug delivery, laser therapy, and workflow integration are reshaping earlier, more individualized glaucoma care.

Joel S. Schuman, MD, FACS, highlights home tonometry, virtual visual fields, and portable OCT devices as promising tools, while noting concerns around data reliability, patient adherence, and reimbursement.

The letter noted the FDA is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD, according to the company.